Although we may not have sufficient power to detect significant changes in our secondary outcomes (tau PET, MRIs, CSF AD biomarkers and cognition), including a nine-month follow-up will help provide preliminary evidence of successful modification of disease trajectory over a one-year period. Here, MAPT is linked to Alzheimer disease.